Study diabetes patients to measure MAFLD in Jiangsu
Part of Hormones & metabolism clinical trials.
This study checks how common a condition called MAFLD is among people with type 2 diabetes in Jiangsu, China. It may help doctors understand how often this liver-related problem occurs and guide future care for people with type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with type 2 diabetes (not other types of diabetes).
- You can have a measurement done using the iLivTouch device (UAP measurement).
- You are able and willing to attend study visits and follow-up.
- You can understand the study and sign written informed consent.
- You will be excluded if you have a different type of diabetes than type 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with fatty liver to learn more about how it progresses and what patterns are common. It may help improve future ways of identifying and monitoring fatty liver.
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
This trial tests a digital health app designed to help people with metabolic-associated fatty liver disease (MAFLD). The app provides diet and exercise guidance to improve liver health.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study follows people who have both type 2 diabetes and fatty liver disease to see how these conditions affect heart health over time. By participating, you'll help researchers learn more about lowering your risk of heart problems.
This study uses a special ultrasound device called iLivTouch to measure liver stiffness. It aims to see if changes in liver stiffness over time can predict serious liver problems in people with metabolic fatty liver disease. If you have MAFLD and your liver is already stiff, this could help doctors monitor your condition.
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.